Ortataxel
|  | |
| Systematic (IUPAC) name | |
|---|---|
| (3aS,4R,7R,8aS,9S,10aR,12aS,13S,13aS)-7,12a-bis(acetyloxy)-4-({(2R,3S)-3-[tert-butoxycarbonyl)amino]-2-hydroxy-5-methylhexanoyl}oxy)-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-6,13a-methano[1,3]dioxolo[8,9]cyclodeca[1,2-d][1]benzoxet-13-yl benzoate | |
| Identifiers | |
| CAS Number | 186348-23-2  | 
| ATC code | None | 
| PubChem | CID 10557575 | 
| ChemSpider | 5293609 | 
| UNII | 8H61Y4E29N  | 
| Chemical data | |
| Formula | C44H57NO17 | 
| Molar mass | 871.92 g/mol | 
| 
 | |
| 
 | |
| (verify) | |
Ortataxel is a drug used in chemotherapy. As of June 2009, Spectrum Pharmaceuticals has the drug is in a Phase 2 clinical trial.
| 
 | ||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Thursday, October 15, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.